Is rituximab safe to use in kidney transplant patients?: Editorial

American Journal of Transplantation

Volumn 10, Issue 1, 2010, Pages 8-9

  Jordan, S C ^a   Glotz, D ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; THYMOCYTE ANTIBODY;

BACTERIAL INFECTION; CELLULAR IMMUNITY; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; EDITORIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INJECTION SITE REACTION; KIDNEY TRANSPLANTATION; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMONIA; POLYOMA VIRUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS REACTIVATION; WORLD HEALTH ORGANIZATION;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; SAFETY;

EID: 72549119543     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02925.x     Document Type: Editorial

References (7)

1. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: A report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 2009 113 : 4834 4840.
2. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009 9 : 244 245.
3. Mclaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-course treatment program. J Clin Oncology 1998 16 : 2825 2833.
4. Van Vollenhoven RF, Emery P, Bingham CO III. et al. Long-term safety of rituximab: follow-up of the RA clinical trials and re-treatment population [EULAR Abstract OP-0026]. Ann Rheum Dis 2009 68.
5. Usui M, Isaji S, Mizuno S, Sakurai H, Uemoto S. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clin Transplant 2007 21 : 24 31.
6. Kamar N, Milioto O, Benedicte P-L et al. Incidence and predictive factors for infectious diseases after rituximab therapy in kidney transplant patients. Am J Transplant (in press).
7. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 359 : 242 251.